Filing Flows › Comparisons › AORT vs PRCT
Artivion vs Procept BioRobotics: AORT and PRCT compared
Artivion is the larger company: $124M of revenue in its latest quarter (Q3 2026) against $98.3M for Procept BioRobotics (Q3 2026). Procept BioRobotics is growing faster (+18% against +9% a year earlier). Artivion is more profitable, with an operating margin of 2.4% against -27.9%.
Where the money goes: AORT and PRCT
Artivion (AORT) · Q3 2026
Artivion, Q3 2026: revenue $124M (+9% year over year), operating margin 2.4%, net loss $7.9M, operating cash flow −$4.6M. The chart follows the revenue to costs, profit and cash.
Procept BioRobotics (PRCT) · Q3 2026
Procept BioRobotics, Q3 2026: revenue $98.3M (+18% year over year), operating margin -27.9%, net loss $26.5M, operating cash flow −$9.0M. The chart follows the revenue to costs, profit and cash.
| Artivion (AORT) | Procept BioRobotics (PRCT) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $124M | $98.3M |
| Revenue growth, Y/Y | +9% | +18% |
| Operating margin | 2.4% | -27.9% |
| Net earnings | −$7.9M | −$26.5M |
| Net margin | -6.4% | -27.0% |
| Operating cash flow | −$4.6M | −$9.0M |
| Market value | — | $1.1B |
| Analysts’ mean target | — | $22.58 |
Where the revenue comes from
Artivion
- Products: $98.2M (79%)
- Preservation services: $25.6M (21%)
Questions
Which is bigger, Artivion or Procept BioRobotics?
Artivion is the larger company: $124M of revenue in its latest quarter (Q3 2026) against $98.3M for Procept BioRobotics (Q3 2026).
Is Artivion or Procept BioRobotics growing faster?
Procept BioRobotics is growing faster (+18% against +9% a year earlier).
Which is more profitable, Artivion or Procept BioRobotics?
Artivion is more profitable, with an operating margin of 2.4% against -27.9%.
More: Artivion earnings · how Artivion makes money · Procept BioRobotics earnings · how Procept BioRobotics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 6, 2026; 10-Q filed Nov 4, 2026). Fiscal quarters can end on different dates. Not investment advice.